​

Abeona Therapeutics Inc. has announced it has received approval from the US Food

and Drug Administration (FDA) for Zevaskyn™ (prademagene zamikeracel, pz-cel),

an autologous cell-based gene therapy for adult and pediatric patients with

recessive dystrophic epidermolysis bullosa (RDEB). Zevaskyn has a Wholesale

Acquisition Cost (WAC) of $3.1 million. It will be available through Qualified Treatment

Centers beginning in the 3rd quarter of 2025.